(Rac) -Ruxolitinib-d9
(Rac) -Ruxolitinib D9 ((Rac) -INCB18424 D9) is the deuterium labeled (Rac) -Ruxolitinib. (Rac) -Ruxolitinib is a JAK2 inhibitor[1].
Product Specifications
CAS Number
[2469553-67-9]
Product Name Alternative
(Rac) -INCB18424-d9; Ruxotinib racemate-d9
UNSPSC
12352005
Target
Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.44
Solubility
10 mM in DMSO
Smiles
N#CCC(C1([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])N2C=C(C=N2)C3=C4C(NC=C4)=NC=N3
Molecular Formula
C17H9D9N6
Molecular Weight
315.42
References & Citations
[1]Yaoyu CHEN, et al. Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. Patent WO2021102258A1|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
More Discoveries
Explore Other Products
Browse additional items from our catalog